These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23262402)

  • 1. The contribution of proteomics to the identification of biomarkers for cutaneous malignant melanoma.
    Bougnoux AC; Solassol J
    Clin Biochem; 2013 Apr; 46(6):518-23. PubMed ID: 23262402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity.
    Greco M; Mitri MD; Chiriacò F; Leo G; Brienza E; Maffia M
    Cancer Lett; 2009 Oct; 283(2):222-9. PubMed ID: 19394758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
    Findeisen P; Zapatka M; Peccerella T; Matzk H; Neumaier M; Schadendorf D; Ugurel S
    J Clin Oncol; 2009 May; 27(13):2199-208. PubMed ID: 19307507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Circulating prognosis markers in melanoma: proteomic profiling and clinical studies].
    Solassol J; Guillot B; Maudelonde T
    Ann Biol Clin (Paris); 2011; 69(2):151-7. PubMed ID: 21464007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cluster analysis of serum proteins in malignant cutaneous melanoma: search for disease markers.
    Ragazzi E; Vogliardi S; Allegri G; Costa CV; Lise M; Rossi CR; Seraglia R; Traldi P
    Rapid Commun Mass Spectrom; 2003; 17(13):1511-5. PubMed ID: 12820221
    [No Abstract]   [Full Text] [Related]  

  • 6. [Profiles of low-molecular proteome spectrum obtained through SELDI-TOF mass spectrometry in the sera of patients with metastatic malignant melanoma: pilot study].
    Lakomý R'; Greplová K; Pilný R; Budinská E; Valík D; Poprach A; Nemecek R; Vyzula R
    Klin Onkol; 2009; 22(5):228-32. PubMed ID: 19886361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum proteomic profiling reveals potential biomarkers for cutaneous malignant melanoma.
    Solassol J; Du-Thanh A; Maudelonde T; Guillot B
    Int J Biol Markers; 2011; 26(2):82-7. PubMed ID: 21607923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical proteomics in breast cancer: a review.
    Gast MC; Schellens JH; Beijnen JH
    Breast Cancer Res Treat; 2009 Jul; 116(1):17-29. PubMed ID: 19082706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating biomarkers in malignant melanoma.
    Alegre E; Sammamed M; Fernández-Landázuri S; Zubiri L; González Á
    Adv Clin Chem; 2015; 69():47-89. PubMed ID: 25934359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in biomarkers for melanoma.
    Griewank KG; Ugurel S; Schadendorf D; Paschen A
    Curr Opin Oncol; 2013 Mar; 25(2):145-51. PubMed ID: 23334230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical proteomics: towards early detection of cancers].
    Solassol J; Boulle N; Maudelonde T; Mangé A
    Med Sci (Paris); 2005; 21(8-9):722-9. PubMed ID: 16115457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Proteomic profiling: the potential of Seldi-Tof for the identification of new cancer biomarkers].
    Solassol J; Marin P; Maudelonde T; Mangé A
    Bull Cancer; 2005 Sep; 92(9):763-8. PubMed ID: 16203265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
    Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
    Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Old and new serological biomarkers in melanoma: where we are in 2009.
    Mouawad R; Spano JP; Khayat D
    Melanoma Res; 2010 Apr; 20(2):67-76. PubMed ID: 20093989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter to the Editor regarding proteomic strategies and biomarker identification in melanoma.
    Phelps A; Murphy MJ
    Clin Biochem; 2013 Sep; 46(13-14):1309. PubMed ID: 23810584
    [No Abstract]   [Full Text] [Related]  

  • 16. Protein profiles in sera of patients with malignant cutaneous melanoma.
    Ferrari L; Seraglia R; Rossi CR; Bertazzo A; Lise M; Allegri G; Traldi P
    Rapid Commun Mass Spectrom; 2000; 14(13):1149-54. PubMed ID: 10867691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass spectrometry-based proteomics: the road to lung cancer biomarker discovery.
    Indovina P; Marcelli E; Pentimalli F; Tanganelli P; Tarro G; Giordano A
    Mass Spectrom Rev; 2013; 32(2):129-42. PubMed ID: 22829143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry.
    Liu XP; Shen J; Li ZF; Yan L; Gu J
    Cancer Invest; 2006 Dec; 24(8):747-53. PubMed ID: 17162557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular markers in malignant cutaneous melanoma: gift horse or one-trick pony?
    Martinez SR; Hoon DS
    J Cell Biochem; 2005 Oct; 96(3):473-83. PubMed ID: 16088931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of hypopharyngeal squamous cell carcinoma using serum proteomics.
    Zhou L; Cheng L; Tao L; Jia X; Lu Y; Liao P
    Acta Otolaryngol; 2006 Aug; 126(8):853-60. PubMed ID: 16846929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.